The Warburg effect: an enduring observation and its evolving interpretations

Who was Otto Warburg?

Otto Warburg (1883-1970) was an experimental genius of cellular biochemistry. He developed the manometric techniques (measurement of oxygen consumption) that enabled the first precise observations of cellular metabolism in vitro. Working with cultures of cancerous and normal cells, he observed dramatic differences in the way these cells produced energy (ATP).

His work was rigorous and his observations precise. What Warburg saw was a real and reproducible phenomenon: cancer cells behaved differently in energetic terms. This observation deserved his interest and that of the scientific community. The general interpretation he drew from it proved more nuanced over time, but this does not invalidate the quality of his empirical observations.

The original observation: increased glycolysis in the presence of oxygen

Warburg's key observation was simple but striking: tumour cells consumed far more glucose and produced far more lactic acid than normal cells, even in the presence of abundant oxygen. Under normal aerobic conditions, healthy cells fully oxidise glucose through mitochondrial respiration (the Krebs cycle plus the respiratory chain), producing 30 to 32 molecules of ATP per glucose.

Tumour cells, on the other hand, appeared to favour anaerobic lactic fermentation, producing only 2 ATP per glucose, even with oxygen available. It was this paradox that Warburg called the "Warburg effect". This observation has been confirmed as real and universal: it is observed in the majority of modern solid tumours.

The initial interpretation: one hypothesis among others

Warburg proposed that this metabolic dysfunction was the root cause of cancer: if the mitochondria of tumour cells were damaged or dysfunctional, they would be unable to use oxygen efficiently. The cells would therefore be "forced" to rely on the less efficient anaerobic glycolysis.

It was an appealing causal hypothesis: mitochondrial dysfunction → glycolytic dependence → unchecked division → cancer. If it were correct, restoring mitochondrial function should theoretically slow down, or even halt, cancer. This reasoning was elegant and captivated the oncological imagination for decades.

The evolution of knowledge: matters become more complicated

From the 1950s onwards, and progressively up to the present day, the techniques of molecular biology have revealed a far more complex and nuanced picture than could have been imagined in Warburg's time.

A confirmed observation, a debated causality

On the one hand, modern studies have confirmed the observation: yes, tumour cells generally have a dominant glycolytic metabolism. This is an established fact and one that can be exploited diagnostically (hence the success of PET scans using radioactive glucose).

On the other hand, several discoveries have complicated the simple causal interpretation:

First discovery: many tumour cells possess functional mitochondria. They are not "forced" to use glycolysis through a lack of an oxidative pathway; they actively choose it. Why? Because glycolysis, although energetically inefficient, is rapid and generates metabolic precursors useful for rapid growth. A constantly growing cell sometimes needs speed rather than pure energy efficiency.

Second discovery: molecular genetics has revealed that certain mutations (notably in oncogenes such as MYC or KRAS) directly drive the adoption of a glycolytic metabolism, independently of the state of the mitochondria. Genetic control outweighs energetic constraints.

Third discovery: there are cancers with a partially oxidative or mixed metabolism, contradicting the idea that all cancers would be uniformly glycolytic owing to mitochondrial dysfunction.

The current state: the Warburg effect confirmed, causality revised

By an interesting irony, the phenomenon observed by Warburg (increased glycolysis in cancer) has been confirmed as universal and useful. The Warburg effect exists; it is a sound observational fact that can be exploited.

However, the causal interpretation that Warburg proposed (mitochondrial dysfunction → glycolysis → cancer) has become more complex. Current evidence suggests instead that metabolism is one element among others in tumour ecology: it affects progression, aggressiveness and interaction with the immune system, without necessarily being the primary cause.

An open scientific question

A valid question remains: does mitochondrial dysfunction play a role in the initiation of cancer, or is it chiefly involved in its progression? Modern research has not settled this definitively. It is precisely this that makes the question scientifically interesting and worthy of continued investigation.

Implications for methylene blue

If mitochondrial dysfunction were the primary cause of cancer, then restoring mitochondrial function (via methylene blue, for instance) should theoretically be a major therapeutic strategy.

If metabolic dysfunction is chiefly a consequence or an amplifying element among other factors, then methylene blue might have an adjuvant rather than a fundamental role.

Between these two views, modern molecular biology leans rather towards the second, yet without having definitively closed the door to metabolic interactions deeper than is generally supposed. This is precisely the debate that serious researchers in cancer metabolism continue to explore.

A fine hypothesis, still under exploration

The Warburg effect remains a robust observation and a relevant scientific question. Warburg saw something real, and his legacy is not a body of definitive answers, but a body of questions that continue to drive research.

Using the Warburg effect to justify a theory of cancer is neither dogmatically correct nor categorically false: it is an exploratory avenue that warrants rigorous investigation. And this is exactly what modern research in cancer metabolism does, remaining a field of active discovery.

For methylene blue specifically, its potential applications in oncology rest on this evolving understanding of the role of metabolism in cancer. As long as this role is not fully elucidated, its therapeutic applications remain exploratory — which does not mean impossible, but rather requiring more thorough validation.